These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. T-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effect. Cruz CR; Bollard CM Haematologica; 2015 Jun; 100(6):709-19. PubMed ID: 26034113 [TBL] [Abstract][Full Text] [Related]
4. Immunotherapy in the context of hematopoietic stem cell transplantation: the emerging role of natural killer cells and mesenchymal stromal cells. Lankester AC; Ball LM; Lang P; Handgretinger R Pediatr Clin North Am; 2010 Feb; 57(1):97-121. PubMed ID: 20307714 [TBL] [Abstract][Full Text] [Related]
5. Advancement and clinical implications of HLA typing in allogeneic hematopoietic stem cell transplantation. Baxter-Lowe LA; Hurley CK Cancer Treat Res; 2009; 144():71-94. PubMed ID: 19779873 [No Abstract] [Full Text] [Related]
6. Clinical implications of immune reconstitution following hematopoietic stem cell transplantation. Peggs KS; Krauss AC; Mackall CL Cancer Treat Res; 2009; 144():131-54. PubMed ID: 19779871 [No Abstract] [Full Text] [Related]
7. Hematopoietic chimerism and tolerance of T cells, B cells, and NK cells. Sykes M; Ohdan H; Manilay JO; Wekerle T; Yang YG Transplant Proc; 1998 Dec; 30(8):4020. PubMed ID: 9865282 [No Abstract] [Full Text] [Related]
8. The expanding horizon of immunotherapy in the treatment of malignant disorders: allogeneic hematopoietic stem cell transplantation and beyond. Tsirigotis P; Shimoni A; Nagler A Ann Med; 2014 Sep; 46(6):384-96. PubMed ID: 24888385 [TBL] [Abstract][Full Text] [Related]
9. Negative depletion of α/β+ T cells and of CD19+ B lymphocytes: a novel frontier to optimize the effect of innate immunity in HLA-mismatched hematopoietic stem cell transplantation. Locatelli F; Bauquet A; Palumbo G; Moretta F; Bertaina A Immunol Lett; 2013; 155(1-2):21-3. PubMed ID: 24091162 [TBL] [Abstract][Full Text] [Related]
12. Strategies to enhance the therapeutic efficacy of autologous hematopoietic stem cell transplantation by posttransplantation adoptive transfer of T cells with engineered graft-versus-tumor activity. Jensen M Biol Blood Marrow Transplant; 2005 Feb; 11(2 Suppl 2):34-9. PubMed ID: 15682174 [No Abstract] [Full Text] [Related]
13. Adoptive Immunotherapies After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies. Xiong Y; Bensoussan D; Decot V Transfus Med Rev; 2015 Oct; 29(4):259-67. PubMed ID: 26282736 [TBL] [Abstract][Full Text] [Related]
14. Natural killer cell receptors: alterations and therapeutic targeting in malignancies. Konjević G; Vuletić A; Mirjačić Martinović K Immunol Res; 2016 Feb; 64(1):25-35. PubMed ID: 26374324 [TBL] [Abstract][Full Text] [Related]
15. Allogeneic hematopoietic transplantation and leukemia: a second chance for T cells? Kuppen PJ Transplantation; 2008 Jan; 85(1):7-8. PubMed ID: 18192904 [No Abstract] [Full Text] [Related]
16. Advantages and clinical applications of natural killer cells in cancer immunotherapy. Ames E; Murphy WJ Cancer Immunol Immunother; 2014 Jan; 63(1):21-8. PubMed ID: 23989217 [TBL] [Abstract][Full Text] [Related]